GW Pharmaceuticals PLC- (NASDAQ:GWPH) Upgraded to “Hold” by Zacks Investment Research

GW Pharmaceuticals PLC- (NASDAQ:GWPH) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday, January 3rd.

According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “

A number of other equities research analysts have also issued reports on GWPH. Leerink Swann restated an “outperform” rating and set a $153.00 price target (down previously from $160.00) on shares of GW Pharmaceuticals PLC- in a report on Monday, October 2nd. Cowen reaffirmed an “outperform” rating and set a $165.00 price objective on shares of GW Pharmaceuticals PLC- in a research report on Monday, October 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $208.00 price objective on shares of GW Pharmaceuticals PLC- in a research report on Monday, October 2nd. ValuEngine downgraded shares of GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. Finally, Goldman Sachs Group reissued a “neutral” rating and issued a $124.00 target price on shares of GW Pharmaceuticals PLC- in a research report on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $148.78.

Shares of GW Pharmaceuticals PLC- (GWPH) opened at $131.97 on Wednesday. GW Pharmaceuticals PLC- has a fifty-two week low of $92.65 and a fifty-two week high of $140.52. The company has a quick ratio of 7.47, a current ratio of 7.59 and a debt-to-equity ratio of 0.02. The company has a market cap of $3,350.00, a P/E ratio of -18.72 and a beta of 2.65.

Hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC acquired a new stake in shares of GW Pharmaceuticals PLC- during the 2nd quarter worth about $70,128,000. Pictet Asset Management Ltd. grew its holdings in GW Pharmaceuticals PLC- by 102.6% during the 3rd quarter. Pictet Asset Management Ltd. now owns 355,263 shares of the biopharmaceutical company’s stock worth $36,056,000 after acquiring an additional 179,911 shares during the last quarter. Redmile Group LLC grew its holdings in GW Pharmaceuticals PLC- by 33.8% during the 2nd quarter. Redmile Group LLC now owns 444,936 shares of the biopharmaceutical company’s stock worth $44,605,000 after acquiring an additional 112,392 shares during the last quarter. AXA bought a new stake in GW Pharmaceuticals PLC- during the 3rd quarter worth about $9,570,000. Finally, Employees Retirement System of Texas bought a new stake in GW Pharmaceuticals PLC- during the 2nd quarter worth about $5,313,000. Institutional investors own 74.57% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “GW Pharmaceuticals PLC- (NASDAQ:GWPH) Upgraded to “Hold” by Zacks Investment Research” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/13/gw-pharmaceuticals-plc-gwph-lifted-to-hold-at-zacks-investment-research.html.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC- (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply